Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
Business13 hours ago5 things to watch on the ASX 200 on Thursday 4 September 2025
-
Noosa News24 hours agoPlan for new apartment tower sparks backlash in West End
-
Business11 hours agoGuess which ASX 200 tech stock Bell Potter just upgraded
-
Noosa News10 hours agoDog owners warned: $834 fine for pets not under control